Skip to Content


Medically reviewed by Last updated on Jul 18, 2019.


(tole NAF tate)

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Aerosol, External:

Athletes Foot Spray: 1% (150 g) [contains sd alcohol 40]

Tinactin: 1% (150 g)

Aerosol Powder, External:

Jock Itch Spray: 1% (130 g) [contains sd alcohol 40b]

LamISIL AF Defense: 1% (133 g)

Tinactin: 1% (133 g)

Tinactin Deodorant: 1% (133 g)

Cream, External:

Antifungal: 1% (14.18 g) [odorless]

Fungi-Guard: 1% (15 g)

Fungoid-D: 1% (113 g) [contains cetyl alcohol, methylparaben, propylene glycol, propylparaben, trolamine (triethanolamine)]

Medi-First Anti-Fungal: 1% (1 ea [DSC])

Tinactin: 1% (15 g, 30 g)

Tinactin Jock Itch: 1% (15 g)

Tolnaftate Antifungal: 1% (114 g [DSC]) [contains cetyl alcohol, methylparaben, polysorbate 80, propylene glycol, propylparaben]

Generic: 1% (15 g, 20 g, 28.3 g, 30 g)

Powder, External:

Anti-Fungal: 1% (45 g)

Podactin: 1% (45 g)

Tinactin: 1% (108 g [DSC])

Generic: 1% (45 g)

Solution, External:

Dr Gs Clear Nail: 1% (18 mL) [contains propylene glycol]

Mycocide Clinical NS: 1% (30 mL) [contains propylene glycol]

The Treatment Formula 3: 1% (15 mL) [contains butylparaben, methylparaben, propylparaben, sesame oil]

Tinaspore: 1% (10 mL)

Generic: 1% (10 mL)

Brand Names: U.S.

  • Anti-Fungal [OTC]
  • Antifungal [OTC]
  • Athletes Foot Spray [OTC]
  • Dr Gs Clear Nail [OTC]
  • Fungi-Guard [OTC]
  • Fungoid-D [OTC]
  • Jock Itch Spray [OTC]
  • LamISIL AF Defense [OTC]
  • Medi-First Anti-Fungal [OTC] [DSC]
  • Mycocide Clinical NS [OTC]
  • Podactin [OTC]
  • The Treatment Formula 3 [OTC]
  • Tinactin Deodorant [OTC]
  • Tinactin Jock Itch [OTC]
  • Tinactin [OTC]
  • Tinaspore [OTC]
  • Tolnaftate Antifungal [OTC] [DSC]

Pharmacologic Category

  • Antifungal Agent, Topical


Distorts the hyphae and stunts mycelial growth in susceptible fungi

Onset of Action

24 to 72 hours

Use: Labeled Indications

Treatment of tinea pedis, tinea cruris, tinea corporis; prevention of tinea pedis

Dosing: Adult

Tinea pedis:

Treatment: Topical: Apply twice daily for 4 weeks

Prevention: Topical: Apply once or twice daily

Tinea corporis, treatment: Topical: Apply twice daily for 4 weeks

Tinea cruris, treatment: Topical: Apply twice daily for 2 weeks

Dosing: Geriatric

Refer to adult dosing.

Dosing: Pediatric

Tinea pedis:

Treatment: Children ≥2 years and Adolescents: Topical: Apply twice daily for 4 weeks

Prevention: Children ≥2 years and Adolescents: Topical: Apply once or twice daily.

Tinea corporis, treatment: Children ≥2 years and Adolescents: Topical: Apply twice daily for 4 weeks.

Tinea cruris, treatment: Children ≥2 years and Adolescents: Topical: Apply twice daily for 2 weeks.


Topical: For external use only; avoid contact with eyes. Wash and dry affected area before drug application. For tinea pedis, also apply to spaces between the toes.

Aerosol, aerosol powder: Shake well prior to use.

Drug Interactions

There are no known significant interactions.

Adverse Reactions

Frequency not defined.

Dermatologic: Contact dermatitis, pruritus, stinging of the skin

Local: Irritation


Concerns related to adverse effects:

• Irritation: Discontinue if sensitivity or irritation occurs.

Special populations:

• Pediatric: Not for self-medication (OTC use) in children <2 years of age.

Other warnings/precautions:

• Appropriate use: For topical use only; avoid contact with eyes. Apply to clean, dry skin. When used for self-medication (OTC use), contact health care provider if condition does not improve within 4 weeks.

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Have patient report immediately to prescriber severe skin irritation (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.